Categories Earnings, Health Care

Allergan (AGN) Q3 earnings preview: Patent issues, AbbVie deal in focus

After securing shareholders’ approval for the takeover deal with AbbVie (ABBV), Allergan (NYSE: AGN) will be publishing its third-quarter results on November 5 at 7:00 am ET. Market watchers are of the view that earnings will decline 1% annually to $4.22 per share. The estimated revenue is $3.88 billion.

The Irish pharmaceutical firm strengthened its pipeline in recent months by securing key regulatory approvals – including Vraylar for the treatment of bipolar depression and Bimatoprost for glaucoma. Allergan’s flagship product Botox continues to be the main growth driver, supported by other key formulations including Lo Loestrin and Ozurdex.

Allergan (AGN) beats Q2 2019 earnings and revenue estimates; lifts FY19 revenue outlook

The positive momentum might help the stock recover from the recent lows. Earnings topped expectations consistently in the trailing quarters, which is expected to be the case this time too.

Also see: Will Allergan-AbbVie merger be intercepted

The ongoing weakness in revenue performance might continue, primarily owing to the recent recall of breast implants that dented customers’ confidence to some extent. Also, the top-line remains under pressure due to competition from the generic market after some of Allergan’s key formulations lost patent recently.

As per initial estimates, the bottom-line will be impacted by a $750 million charge related to the settlement of lawsuits filed by customers against the company’s subsidiary Forest with regard to its Alzheimer’s drugs.

Q2 Performance

In the second quarter, adjusted earnings declined modestly to $4.38 per share on revenues of $4.09 billion, down 1% year-over-year. The results, however, topped expectations.

Bristol-Myers Squibb (BMY) this week reported higher revenues and earnings for the September-quarter, aided by strong sales performance by its key products. Earnings rose 7% annually to $1.17 per share, on revenues of $6 billion.

Also Read:  Glu Mobile slips about 10% after it reports loss for Q4

AbbVie Deal

Earlier this year, Allergan agreed to be acquired by AbbVie for about $63 billion in a cash-and-stock deal. The market will be looking for updates on the progress of the takeover procedures when the management conducts the post-earnings conference call.

Related: Allergan Q1 2019 Earnings Call Transcript

Allergan lost significant market share over the last several years and slipped to a six-year low a few months ago. The stock bounced back in the following weeks and gained steadily since then. It is up 23% since then.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

MongoDB (MDB) has what it takes to end the losing streak. Here’s why

An innovative product portfolio that is capable of outshining the legacy databases has helped MongoDB (NASDAQ: MDB) stay largely unaffected by the market turmoil so far. Of late, the database

Macy’s (M) confirms Q1 loss; expects gradual sales recovery

Retailer Macy's (NYSE: M) posted mixed results for its first quarter of 2020. While the topline missed the market's estimates, bottom line topped the targets. There were no change in

STZ Earnings: Key quarterly highlights that you need to know from Constellation Brands Q1 financial results

Constellation Brands (NYSE: STZ) today announced its first quarter financial results for the period ended May 31, 2020. First quarter net loss was $177.9 million, or $0.94 per share, compared